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Background: Antipsychotic-induced weight gain andmetabolic abnormalities are one of
the major challenges in the treatment of psychosis, contributing to the morbidity, mortality
and treatment non-adherence. Different approaches were used to counteract these
side effects but showed only limited or short-term effects. This study aims to analyse
the effects of a long-term multimodal treatment program for first episode psychosis on
antipsychotic-induced metabolic changes.
Methods: We enrolled 71 patients with first episode psychosis treated at the Zagreb
University Hospital Centre from 2016 until 2018. Participants were assigned to one of
the two groups: day hospital program vs. treatment as usual (TAU). Outcomes were:
body weight, blood glucose, lipids and cholesterol, psychopathology and global level of
functioning during the 18-months follow-up.
Results: Although the TAU group gained more weight and had higher increase of blood
glucose, while the day hospital group had a higher increase in total cholesterol at 18th
month follow-up, after the adjustment for age, gender and baseline measures, the type
of treatment was not significantly associated with any of the primary outcome measures.
Patients’ psychopathology measures significantly decreased and their functional level
significantly increased at month 18th in both groups.
Conclusion: While both types of treatment were effective in reducing psychopathology
and restoring the patients’ level of functioning, both were relatively ineffective in
counteracting antipsychotic-inducedmetabolic abnormalities and antipsychotic-induced
weight gain.
Keywords: antipsychotics, schizophrenia, first episode psychosis, metabolic abnormalities, weight gain,
psychosocial intervention, day hospital
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INTRODUCTION
The second generation antipsychotics (SGA) are considered as
the first line treatment for schizophrenia spectrum disorders.
Unfortunately, most SGA are associated with a significant
weight gain causing subsequent development of metabolic
syndrome and increasing the risk of cardiovascular morbidity
and mortality (1). In addition, significant weight gain may
cause non-adherence to medication (2) and subsequently lead
to relapses (3). Risk factors for antipsychotic-induced weight
gain and metabolic abnormalities include polypharmacy (4),
olanzapine or clozapine monotherapy (5), female gender, lower
initial body mass index (6), positive treatment response (7)
and family history of diabetes (8). The highest increase of
weight gain is seen particularly during the first few months
of treatment (9). Different strategies were used to counteract
these side effects, such as changes of medication regimes (e.g.,
switch to antipsychotics with a lower propensity to cause
weight gain, addition of drugs that may suppress appetite)
(10, 11), psychoeducation (12) and exercise (13). However, in the
clinical practice,antipsychotic-induced metabolic disturbances
still remain one of the most important obstacles for effective
treatment. During the last 20 years, multimodal programs for
treatment of patients with first episode psychosis have been
developed worldwide (14). These services usually incorporate
a set of psychopharmacological and psychosocial approaches
following individualized treatment plans. Patients with the
first episode psychosis treated in our hospital are offered this
kind of treatment through the day hospital setting. As this
multimodalprogramme incorporatesstructured psychoeducation
on healthy lifestyle and side effects of medication and
unstructured exercise, we hypothesized that it may have
advantage over treatment as usual (TAU) in counteracting
antipsychotic-induced metabolic changes. Thus, we aimed to
analyze the effects of the multimodal treatment of first episode
psychosis on the antipsychotic-induced metabolic changes over
an 18-months period. In addition, we explored the relationship
of patients’ psychopathology and functioning and the type of
treatment.
METHODS
Participants and Protocol
This study was nested within the prospective cohort study:
“Biomarkers in schizophrenia-integration of complementary
methods in longitudinal follow up of first episode psychosis
patients.” The sample consisted of patients admitted to Zagreb
University Hospital Centre (ZUHC), between 2016 and January
2018. Adult patients with the first psychotic episode pertaining
to the schizophrenia spectrum diagnosed according to the
research criteria of the International Classification of Disorders
(ICD-10) (15) by the consensus of two experienced psychiatrists,
were recruited to participate in the study. Exclusion criteria
included the presence of somatic disorders/status, and use
of medication and other substances with possible effects on
metabolic features (diabetes, hypercholesterolemia, pregnancy
or lactation, antidiabetic drugs, hypolipemics), and psychotic
disorders due to organic causes. All patients treated at the ZUHC
for first acute episode psychosis during the study period meeting
those criteria were invited to participate in the study. After
the patients reached the subacute phase of psychosis (usually
in the first few weeks of antipsychotic treatment), they chose
one of the two treatment groups according to their preference:
day hospital treatment (which included a combination of
pharmacological approach and psychosocial approaches (group
psychotherapy, social skills training, metacognitive training,
creative workshops, family therapy, and psychoeducation
including topics on healthy lifestyle, antipsychotic-induced
metabolic changes, diet encouragement and unstructured
exercise in a closed group, three times a week, but decreasing
in the number of weekly sessions over 12 months) or TAU
(short outpatients visits usually once a month). The patients
were followed-up for 18 months and assessed at baseline and
month 18th for sociodemographic and clinical data, including
data on lifestyle (smoking, drinking, drug use), metabolic
parameters [blood glucose, total cholesterol, high density
lipoprotein (HDL), low density lipoprotein (LDL), triglycerides],
weight, psychopathology with Positive and Negative Syndrome
Scale, PANSS (16), quality of life using the World Health
Organization Quality of Life Assessment, WHOQOL-BREF
(17) and level of functioning using the Global Assessment
of Functioning, GAF (18). Primary outcome of the study
were metabolic side- effects assessed at 18-month. Secondary
outcome included patients’ psychopathology assessed at
18-month.
The study protocol was approved by the Ethics Committee of
the ZUHC. The study was executed in accordance with World
Medical Association Declaration of Helsinki 2013.
Statistical Analysis
Changes from the baseline values to values at the last assessment
were presented with absolute and relative changes and their
95% confidence intervals. Differences in primary and secondary
outcome measures between the two groups were analyzed using
multivariable analysis of covariance (MANCOVA), adjusted for
age, sex and baseline measurements (metabolic and BMI, and
psychopathology). As the assumptions for MANCOVA we tested
linearity of correlations between dependent and independent
variables and multivariate normality by inspection of scatter
plots, non-existence of univariate outliers and homogeneity
of regression slopes, and the equality of error variances by
Leven’s test. The statistical significance was set at p < 0.05.
Statistical data analysis was performed using the R Core
Team (21).
RESULTS
We recruited 71 patients in the study and treated with day
hospital treatment (n = 21) or TAU control group (n = 50).
Sociodemographic and clinical characteristics at baseline are
given in Table 1. The reasons for not choosing daily hospital over
TAU were as follows: significant travel distance from hospital
(N = 25), being employed or regular student with obligations
several days per week and thus unable to attend the sessions
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TABLE 1 | Baseline participants’ characteristics.
Day hospital
(n = 21)
TAU
(n = 50)
Male gender 12 (57.1) 33 (66)
Age (years), median
(IQR)
24 (21–25) 25 (22–33)
Being single 18 (85.7) 38 (76)
Years of education,
mean (SD)
14 (3.2) 14 (4.3)
Employed 3 (14.3) 11 (22)
Age of first contact with
psychiatry, median
(IQR)
23 (19–25) 25 (20–31)
Number of
cigarettes/day, mean
(SD)
10 (11) 8 (12)
Occasional drug use 11 (54.2) 21 (42)
Occasional alcohol use 1 (4.7) 4 (8)
MAIN ANTIPSYCHOTIC
amisulpirid or
aripiprazole
5 (23.8) 5 (10)
fluphenazine or
haloperidol
2 (9.5) 8 (14)
clozapine, olanzapine,
quetiapine
8 (38.1) 21 (42)
risperidone,
paliperidone
6 (28.6) 16 (34)
More than one
antipsychotic
10 (47.6) 21 (42)
Mood stabilizers 3 (14.3) 12 (24)
Anxiolytics/hypnotics 6 (28.6) 17 (34)
Anticholinergics 5 (23.8) 11 (22)
Antidepressants 3 (14.3) 4 (8)
Data are presented as n (%), unless stated otherwise.
IQR, interquartile range; SD, standard deviation.
(N = 11), being older than the majority of group participants
and do not felt as fitting the group (N = 5) and preferring the
individual over group treatment (N = 10).
During the study period, 12 patients from the TAU group
(24%) were re-hospitalized due to relapses, all because of
non-adherence to medication, and 3 patients from the day
hospital group (14.2%). At the final assessment, patients
in the day hospital group were treated with amisulpiride
or aripiprazole (n = 8, 38.1%), clozapine/quetiapine
/olanzapine (n = 5, 23.8%) or paliperidone/risperidone
(n = 4, 19%), or stopped any antipsychotics (n = 4,
19%); a significant number of patients had at least one
additional medication (another antipsychotic (n = 7, 33.3%),
sedative/hypnotic (n = 1, 4.8%), mood stabilizer (n = 3,
14.3%), antidepressant (n = 6, 28.6%), 3 anticholinergic (n = 2,
9.5%)); patients in the TAU were treated with amisulpiride
or aripiprazole (n = 15, 30%), haloperidol/fluphenazine
(n = 3, 6%), clozapine/quetiapine/olanzapine (n = 13, 26%)
or paliperidone/risperidone (n = 15, 30%), or stopped any
antipsychotics (n = 4, 8%); a significant number of patients
had at least one additional medication (another antipsychotic
(n = 20, 40%), sedative/hypnotic (n = 6, 12%), mood stabilizer
(n = 10, 20%), antidepressant (n = 9, 18%), 3 anticholinergic
(n= 7, 14%)).
Metabolic Outcomes Over the Longitudinal
Follow-Up
Changes of the metabolic features and BMI, as well as
changes in symptoms over the 18-months longitudinal follow-
up are given in Table 2. The associations of type of treatment
(day hospital vs. TAU) and primary outcomes at 18-month
data were analyzed using MANCOVA, with age, gender and
baseline metabolic features and baseline BMI as covariates. The
associations of type of treatment and psychopathology at 18-
month data were analyzed using MANCOVA, with age, gender
and baseline PANSS-positive, PANSS-negative, PANSS-general
as covariates. The type of treatment: day hospital vs. TAU,
was not significantly associated with any of the primary or
secondary outcome measures, after the adjustments, as follows
BMI [F(1, 38) = 0.00; p = 0.959; η
2
= 0.00], triglycerides
[F(1, 38)= 0.64; p= 0.429, η
2
= 0.017], cholesterol [F(1, 38)= 2.29;
p = 0.138, η2 = 0.057], LDL cholesterol [F(1, 38) = 2.72;
p = 0.107; η2 = 0.067], HDL cholesterol [F(1, 38) = 0.00;
p = 0.975; η2 = 0.00], glucose in blood [F(1, 38) = 0.46;
p = 0.504; η2 = 0.012]; PANSS-positive [F(1, 63) = 2.17;
p = 0.146; η2 = 0.03]; PANSS-negative [F(1, 63) = 0.03; p = 0.86;
η
2
= 0.00]; PANSS-general [F(1, 63) = 0.57; p= 0.454; η
2
= 0.00]
(Table 2).
DISCUSSION
We have assessed the effects of a multimodal psychosocial
intervention on the antipsychotic-induced weight gain and
metabolic changes in a moderate sample of first episode
psychosis over a longer period. Overall, we did not confirm
the hypothesis that a general multimodal program is more
effective in counteracting weight gain or antipsychotic-induced
metabolic abnormalities compared to TAU in patients with first
episode psychosis over a longer follow-up period. In fact, both
approaches seem to be rather effective for restoring patients’
level of functioning, but less effective to counteract antipsychotic-
induced weight gain and metabolic abnormalities, as the increase
in body mass index and metabolic changes are significant over
18-months.
Unfortunately, this is in line with other studies which found
that different interventions (lifestyle, psychoeducation, exercise)
are of limited effectiveness when it comes to antipsychotic-
induced weight gain or metabolic changes over a longer
time period (e.g., 18-months of antipsychotic-treatment) (19,
20). This is also in line with the results of our previous
study performed at the ZUHC, where we found no effects
of the PsyLOG m-health intervention compared to TAUin
preventing antipsychotic-induced weight gain and metabolic
changes over 6 months follow-up (22). However, it is also
possible that patients with first episode of psychosis are far
more vulnerable group compared to patients with multiple
episodes of psychosis when it comes to antipsychotic-induced
weight gain. In fact, these patients usually have several risk
Frontiers in Psychiatry | www.frontiersin.org 3 October 2018 | Volume 9 | Article 488
Rojnic Kuzman et al. Treatment of Antipsychotic-Induced Metabolic Changes
TABLE 2 | Changes of the primary and secondary outcomes according to the treatment group during the 18 months follow up.
Baseline At 18th month Absolute changes (95%
CI)
Relative changes (%)
(95% CI)
Day hospital
(n = 21)
TAU
(n = 50)
Day hospital
(n = 21)
TAU
(n = 50)
Day hospital
(n = 21)
TAU
(n = 50)
Day hospital
(n = 21)
TAU
(n = 50)
PRIMARY OUTCOME
BMI (kg/m2) 23 (3.0) 24 (3.6) 24 (3.7) 25 (4.2) 0.91 (−0.02
to 2.16)
2.14 (1.13 to
3.31)
4 (0 to 9) 9 (5 to 14)
Triglycerides
(mmol/l)
1.3 (0.69) 1.3 (0.62) 1.7 (2.24) 1.4 (0.82) 0.66 (−0.33
to 2.41)
0.17 (−0.14
to 0.43)
98 (−18 to
331)
21 (−3 to 43)
Total cholesterol
(mmol/l)
4.3 (0.56) 4.7 (0.99) 4.9 (0.94) 4.7 (0.92) 0.49 (0.06 to
1.02)
0.05 (–.41 to
0.46)
11 (1 to 23) 4 (−5 to 14)
HDL cholesterol
(mmol/l)
1.3 (0.33) 1.5 (0.39) 1.4 (0.41) 1.4 (0.45) 0.07 (−0.03
to 0.18)
−0.03 (−0.14
to 0.07)
6 (−2 to 15) −1 (−8 to 6)
LDL cholesterol
(mmol/l)
2.4 (0.49) 2.6 (0.91) 3.0 (0.94) 2.7 (0.84) 0.40 (−0.04
to 0.91)
0.03 (−0.33
to 0.39)
14 (−21 to
36)
9 (−5 to 23)
Blood glucose
(mmol/l)
5.4 (2.77) 4.9 (0.61) 4.9 (0.81) 5.4 (1.13) −0.92 (−3.53
to 0.61)
0.65 (0.21 to
1.16)
−2 (−21 to
14)
14 (5 to 24)
SECONDARY OUTCOMES
PANSS-positive 25 (8.5) 25 (8.9) 9 (3.99) 11 (7.2) −15.3 (−21
to −9.57)
−15.4 (−19.4
to −11.1)
−58 (−71
to−42)
−55 (−67 to
−43)
PANSS-negative 24 (7.2) 24 (7.6) 13 (4.86) 14 (6.6) −10.5 (−12.7
to −7.8)
−11.5 (−14.2
to−8.6)
−46 (−54 to
−35)
−45 (−54 to
−35)
PANSS-general 50(11.3) 51 (10.5) 24 (7.6) 26 (10.3) −25.2 (−31
to −19.1)
−28.9 (−33
to −24.3)
−53 (−61 to
−44)
−56 (−61 to
−49)
GAF, median (IQR) 20 (15 to 35) 23 (15 to 30) 85 (80 to 90) 85 (63.8 to
91.2)
58.2 (46.7 to
68.9)
57.4 (52 to
62.6)
314 (189
to448)
283 (216 to
359)
Data are presented as mean (standard deviation) if not stated otherwise.
CI, confidence interval; IQR, interquartile range.
factors for significant antipsychotic-induced weight gain such
as lower initial body weight, better treatment response and
first treatment with antipsychotics. Furthermore, while being
correlated to a certain extent, some of these antipsychotic-
induced metabolic abnormalities, such as diabetes, often occur
independently of weight gain, and thus can be counteracted only
by close monitoring (23).
We did not analyze the effect of medication thoroughly.
As most of the patients were treated with polypharmacy at
different stages of treatment it is difficult to assess the effect
of medication on weight gain and metabolic changes in this
study. Although the majority of guidelines suggest monotherapy
in the treatment of psychosis, polypharmacy is widespread
in psychiatric practice worldwide (4), including the region
where this study was performed (24). Thus, it is probably not
sufficient to recommend monotherapy as the main strategy
to counteract antipsychotic-induced weight gain and metabolic
abnormalities as it is fair to assume that clinicians probably
decide to use polypharmacy to treat complex clinical symptoms.
The relatively high levels of functioning and significant decrease
of the severity of psychopathology in these patients after 18-
months of treatment suggest that effectiveness of treatment
in terms of functioning is the main goal of treatment, while
antipsychotic-induced weight gain or metabolic changes are
regarded as a less important at best. However, acknowledging
the effect of metabolic abnormalities on morbidity, more focused
strategies to counteract these side effects are needed. While
several interventions involving exercise proved to be efficient
over a shorter period, this effect is lost over a longer period (19,
20). As the negative effects of metabolic abnormalities became
apparent over time, it is crucial to sustain the effects of these
interventions, possibly with a combination with psychosocial
or behavioral interventions focused on sustaining motivation
to exercise or regular supervision of exercise over a longer
period (25). Therefore, finding a suitable program that could help
sustaining the motivation for the continuation of exercises over a
longer period still remains a treatment challenge.
LIMITATIONS OF THE STUDY
First, we did not use a randomized controlled design to assign
the patients to the assessment groups, but we used a naturalistic
design. While randomized control design is considered as
standard for assessing the efficacy of an intervention, naturalistic
design may mirror the real-life situation better. Furthermore, it
could be argued that since the patients were choosing themselves
one the two treatment options (day hospital or TAU) there may
be systematic difference between them in aspects not measured in
the study, e.g., motivation, adherence, etc. which may influence
metabolic outcomes. Finally, we cannot exclude the effects of
other factors not included in the study, such as personality styles,
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eating habits and levels of activity during the studied period on
metabolic outcomes.
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